Background: The World Health Organization (WHO) 2021 classification of central nervous system (CNS) tumors classified astrocytoma isocitrate dehydrogenase-mutant (A IDHm) with either microvascular proliferation and/or necrosis or homozygous deletion of CDKN2A/B as CNS grade 4 (CNS WHO G4), introducing a distinct entity and posing new challenges to physicians for appropriate management and prognostication.
Patients And Methods: We retrospectively collected information about patients diagnosed with A IDHm CNS WHO G4 at three reference neuro-oncological Italian centers and correlated them with survival.
Results: A total of 133 patients were included. Patients were young (median age 41 years) and most received post-operative treatment including chemo-radiation (n = 101) and/or temozolomide maintenance (n = 112). With a median follow-up of 51 months, the median overall survival (mOS) was 31.2 months, with a 5-year survival probability of 26%. In the univariate analysis, complete resection (mOS: 40.2 versus 26.3 months, P = 0.03), methyl-guaninemethyltransferase (MGMT) promoter methylation (mOS: 40.7 versus 18 months, P = 0.0136), and absence of telomerase reverse transcriptase (TERT) promoter mutation (mOS: 40.7 versus 18 months, P = 0.0003) correlated with better prognosis. In the multivariate models, lack of TERT promoter mutation [hazard ratio (HR) 0.23, 95% confidence interval (CI) 0.07-0.82, P = 0.024] and MGMT methylation (HR 0.40, 95% CI 0.20-0.81, P = 0.01) remained associated with improved survival.
Conclusions: This is the largest experience in Western countries exploring the prognostic signature of patients with A IDHm CNS G4. Our results show that MGMT promoter methylation and TERT promoter mutation may impact clinical outcomes. This may support physicians in prognostication, clinical management, and design of future studies of this distinct diagnostic entity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179079 | PMC |
| http://dx.doi.org/10.1016/j.esmoop.2024.103485 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel triangle papilla access approach for interdental bone defect regeneration: A case study.
Clin Adv Periodontics
January 2025
Department of Dentistry and Oral Surgery, Keio University School of Medicine, Tokyo, Japan.
Background: Successful periodontal regeneration depends on primary wound closure and interdental papilla preservation. In this case study, we introduce a novel triangle papilla access approach (T-PAA) performed under a surgical microscope for treating interdental bone defects. In this novel approach, buccal incisions were used to access root surfaces and bone defects, avoiding interdental papilla incisions and preventing papillary collapse and necrosis.
View Article and Find Full Text PDFObservational Characterization of the Retreatment Course of Patients With Thyroid Eye Disease.
J Neuroophthalmol
January 2025
Scheie Eye Institute (YC, TL, SW, TP, PAA, G-sY, CAB, MAT), University of Pennsylvania, Philadelphia, Pennsylvania; Divisions of Neuro-ophthalmology (MAT), Oculoplastics (CAB), and Biostatistics (PAA, G-sY), Kansas Health Science Center, Kansas College of Osteopathic Medicine; and Kansas Health Science Center (GM), Kansas College of Osteopathic Medicine, Kansas, Missouri.
Background: To characterize the retreatment course of patients with thyroid eye disease (TED), who had reactivation after initial therapy with teprotumumab.
Methods: This was a single-center longitudinal cohort study of patients who received an initial course of teprotumumab for active TED and were followed for at least 6 months. Reactivation was defined as the increase of proptosis of 2 mm or more or an increase in Clinical Activity Score (CAS) of two points or more, as adapted from the Optic-X study.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Nat Med
January 2025
Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, CO, USA.
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors.
View Article and Find Full Text PDFInhalation exposure to cross-linked polyacrylic acid induces pulmonary disorders.
Toxicology
January 2025
Department of Occupational Pneumology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka 807-8555, Japan. Electronic address:
Article Synopsis
- - Organic polymers like cross-linked polyacrylic acid (CL-PAA), widely used in various products, have been linked to severe lung diseases, prompting research into the effects of inhalation exposure rather than just instillation.
- - The study involved two exposure durations (5 days and 13 weeks) with male F344 rats, revealing that both short- and long-term exposure to CL-PAA caused significant inflammation, increased neutrophil activity, and lung fibrosis, especially at higher concentrations.
- - Administration of the antioxidant N-acetylcysteine (NAC) reduced the adverse effects of CL-PAA, decreasing inflammation markers and improving overall lung tissue health, indicating it may offer a protective benefit against oxidative stress-induced
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma.
BMC Cancer
November 2024
Department of Dermatology, University of Kiel, Kiel, Germany.
Background: Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety data from the interim analysis of the real-world NISSO study.
Methods: NISSO is an ongoing non-interventional, multinational, post-authorization safety study (NCT04066504).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!